Already on metformin
type 2 diabetes metformin inadequate glycemic control add-on therapy
| Test | Result | Status | Normal |
|---|---|---|---|
| HbA1c | 8.32% | ⬆ HIGH | <5.7% (non-diabetic); Goal of therapy <7.0% |
| Average Blood Glucose | 192.08 mg/dL | ⬆ HIGH | 80-140 mg/dL (good control) |
| Serum Triglycerides | 171.96 mg/dL | ⬆ BORDERLINE HIGH | Desirable <150 mg/dL |
| Test | Result | Normal |
|---|---|---|
| Total Cholesterol | 168.64 mg/dL | Desirable <200 |
| HDL | 48.32 mg/dL | 35-79.5 |
| LDL | 85.93 mg/dL | 60-165 |
| VLDL | 34.39 mg/dL | 20-50 |
| Cholesterol/HDL Ratio | 3.49 | Low Risk (3.32-4.40) |
| LDL/HDL Ratio | 1.78 | Low Risk (<3.0) |

| Priority | Best Add-On | Notes |
|---|---|---|
| Proven CV benefit / multiple risk factors (age 58M is a risk factor) | SGLT2 inhibitor (empagliflozin, dapagliflozin) or GLP-1 RA (semaglutide, liraglutide) | Guidelines strongly prefer these first |
| Weight loss needed | GLP-1 RA or SGLT2 inhibitor | Both cause weight loss; GLP-1 RA also reduces triglycerides |
| Cost-conscious | Sulfonylurea (glimepiride) or TZD (pioglitazone) | Effective but SU causes weight gain and hypoglycemia risk |
| Low hypoglycemia risk | DPP-4 inhibitor (sitagliptin), GLP-1 RA, SGLT2i | All three |
Disclaimer: This analysis is for informational purposes only and is not a substitute for consultation with the treating physician. All medication changes should be made by a qualified doctor who knows the full clinical picture.
Snake bite management
"snakebite" AND "management" AND "antivenom"
Key fact: 70% of all snakebites are from non-venomous species. Of bites by venomous snakes, only ~50% actually envenomate the patient (the rest are "dry bites"). - Park's / Government of India National Protocol 2007
| Venom Type | Mechanism | Key Species | Clinical Effects |
|---|---|---|---|
| Cytotoxic / Haemotoxic | Tissue digestion, haemolysis, destroys endothelial lining | Vipers, Russell's viper | Local necrosis, swelling, coagulopathy, DIC, haemorrhage |
| Neurotoxic | Blocks neuromuscular transmission | Cobras, kraits, coral snakes, sea snakes | Ptosis, dysphagia, diplopia, respiratory paralysis |
| Mixed | Both effects | Some cobras, spitting cobras | Combined local + systemic |


| Harmful Practice | Reason |
|---|---|
| Tourniquets / tight ligatures | Cause ischaemia; do not prevent systemic envenomation |
| Incision and suction | Worsens local tissue damage, increases infection risk; ineffective |
| Ice application | Causes additional tissue injury |
| Alcohol / stimulants | Vasodilators - accelerate venom absorption |
| Seeking traditional healers first | Causes critical life-threatening delays |
| Electric shock "therapy" | No evidence; dangerous |
| Pressure immobilization for viper bites | Concentrates necrotizing venom locally - worsens tissue damage |
| Category | Signs |
|---|---|
| Local | Rapid progressive swelling involving >half the bitten limb within hours; advancing edge >10 cm/h |
| Haematological | Positive 20WBCT (non-clotting blood), thrombocytopenia, active bleeding |
| Neurological | Ptosis, ophthalmoplegia, respiratory distress, bulbar palsy |
| Cardiovascular | Hypotension, shock, ECG changes |
| Renal | Oliguria, dark urine, rising creatinine |
| Reaction | Time | Management |
|---|---|---|
| Early anaphylaxis | Within 10-180 min | Stop infusion immediately. Give adrenaline 0.5 mg IM (thigh). Antihistamines IV. Steroids IV. Restart when controlled at slow rate (5-10 mL/h, titrate up). |
| Pyrogenic reaction | 1-2 hours | Paracetamol, slow infusion rate |
| Serum sickness | 1-2 weeks later | Oral prednisolone 1-2 mg/kg/day, taper over 1-2 weeks; antihistamines |
COMMUNITY (First Aid)
└─ Reassure, immobilize, remove jewellery, transport FAST
PRIMARY HEALTH CENTRE
└─ ABC assessment, 20WBCT, antivenom if available
└─ Paracetamol analgesia (NOT NSAIDs)
└─ IV saline for shock
└─ Transfer if not improving or antivenom unavailable
DISTRICT HOSPITAL
└─ Full bloods, ECG, urinalysis
└─ Antivenom (repeat doses as needed)
└─ Neostigmine/atropine for neurotoxic
└─ Intubation + ventilation for respiratory failure
└─ Dialysis for AKI
REFERRAL / SPECIALIST HOSPITAL
└─ ICU monitoring
└─ Advanced surgical management (skin grafting)
└─ Haemodialysis
└─ Renal/surgical specialities as needed
Snake bite management
| Type | Species | Features |
|---|---|---|
| Neurotoxic | Cobra, Krait, Coral snake | Ptosis → respiratory failure |
| Haemotoxic/Cytotoxic | Russell's Viper, Saw-scaled Viper | Coagulopathy, local necrosis, AKI |
| Mixed | Some cobras | Both local + systemic |
| ✅ DO | ❌ DO NOT |
|---|---|
| Reassure, keep calm | Apply tourniquet |
| Immobilize limb (splint) | Incise or suck the wound |
| Remove jewellery/tight clothing | Apply ice |
| Clean wound, cover with dressing | Give alcohol/stimulants |
| Transport IMMEDIATELY | Seek traditional healers first |
| Photograph snake from safe distance | Try to catch the snake |
| Pressure-immobilization bandage (elapids only) | Pressure bandage for viper bites |
| Reaction | Timing | Treatment |
|---|---|---|
| Anaphylaxis | 10-180 min | Stop infusion → Adrenaline 0.5 mg IM → Antihistamine + steroid IV → Restart slowly |
| Pyrogenic | 1-2 hr | Paracetamol, slow rate |
| Serum sickness | 1-2 weeks | Prednisolone 1-2 mg/kg/day, taper |
| Complication | Management |
|---|---|
| Respiratory paralysis | Intubation + mechanical ventilation (days to weeks); Neostigmine + Atropine trial (cobra) |
| Coagulopathy | Antivenom first; FFP/blood only AFTER adequate antivenom |
| AKI | IV fluids, monitor urine output; dialysis if oliguric |
| Local necrosis | Tetanus prophylaxis, antibiotics if wound manipulated, surgical debridement |
| Compartment syndrome | More antivenom first; fasciotomy only if pressure confirmed >30-40 mmHg post-antivenom |
| Rhabdomyolysis | IV fluids, urine alkalinization, monitor CK |
Neurologic snake bite
"neurotoxic snakebite" AND "neostigmine" OR "elapid envenomation" AND "treatment"
| Snake | Toxin Type | Key Feature |
|---|---|---|
| Common Krait (Bungarus caeruleus) | Pre-synaptic neurotoxin | Bites at night while victim sleeps; only muscular paralysis, minimal local signs; most dangerous neurologic snake in India |
| Indian Cobra (Naja naja) | Post-synaptic neurotoxin | Both convulsions AND paralysis; local necrosis may dominate |
| King Cobra | Post-synaptic | Massive envenomation, rapid onset |
| Sea Snakes | Pre-synaptic + myotoxin | Polymyositis, myoglobinuria, renal failure |
| Region | Species | Notes |
|---|---|---|
| Africa | Black mamba, Green mamba | Near 100% fatal untreated; extremely rapid onset |
| Australia | Taipan, Tiger snake, Brown snake, Death adder | Some of the most toxic venoms known |
| Americas | Coral snake (Micrurus spp.) | Delayed onset (2-5 hrs); no local swelling |
| Asia | Cobras, Kraits | Major burden of neurotoxic deaths |
Fatal dose (dried venom): Krait 6 mg; Cobra 12 mg; Russell's viper 15 mg; Echis 8 mg. Krait venom is gram-for-gram the most dangerous of India's Big Four. - Essentials of Forensic Medicine & Toxicology, 36th Ed. 2026
NEUROMUSCULAR JUNCTION
Motor nerve Synaptic cleft Muscle end plate
(pre-synaptic) (post-synaptic)
ACh vesicles ──────────────────────────► ACh receptors
■ PRE-SYNAPTIC toxins: ■ POST-SYNAPTIC toxins:
(Krait β-bungarotoxin, (Cobra α-neurotoxin)
Taipan, Sea snake) Block ACh receptors
Destroy nerve terminal externally (reversible)
→ IRREVERSIBLE damage → REVERSIBLE with antivenom
→ Nerve must regrow (days-weeks) + neostigmine
| Pre-synaptic Neurotoxin | Post-synaptic Neurotoxin | |
|---|---|---|
| Species | Krait, Taipan, Sea snake | Cobra, Death adder |
| Mechanism | Destroys ACh release apparatus at motor nerve terminal | Blocks nicotinic ACh receptor on muscle end-plate |
| Reversibility | IRREVERSIBLE once binding occurs - antivenom cannot undo damage already done | REVERSIBLE - antivenom + neostigmine may restore function |
| Neostigmine response | Poor/no response | Good response |
| Key implication | Give antivenom EARLY before paralysis advances | Earlier reversible; neostigmine trial worthwhile |
EARLY (1st signs)
↓ Ptosis (drooping of eyelids) ← most consistent early sign
↓ Ophthalmoplegia (eye muscle paralysis, diplopia)
↓ Fixed/constricted pupils
↓ Facial muscle weakness
↓
INTERMEDIATE
↓ Dysphagia (difficulty swallowing) ← aspiration risk begins
↓ Dysphonia (altered voice, dysarthria)
↓ Excessive salivation
↓ Jaw weakness (trismus in sea snakes)
↓ Limb weakness (ascending from legs)
↓
LATE / LIFE-THREATENING
↓ Diaphragm and intercostal muscle paralysis
↓ Respiratory failure ← MAIN CAUSE OF DEATH
↓ Hypoxic cardiac arrest
Cobra bites may be an exception - some cobras (especially spitting cobras) cause significant local necrosis alongside neurological effects. - Tintinalli's Emergency Medicine
| Syndrome No. | Type | Local Effects | Circumstance | Snake |
|---|---|---|---|---|
| 4 | Neurotoxic paralysis | Minimal/none | - | Cobra |
| 4A | Neurotoxic paralysis | Minimal/none | Bitten on land, while sleeping on ground | Krait |
| 4B | Neurotoxic paralysis | Minimal/none | At sea/water, with or without myalgia | Sea snake |
| Test | Expected Finding | Significance |
|---|---|---|
| CBC, coagulation | Normal | Helps distinguish from viper |
| 20WBCT | Clots normally | Confirms no coagulopathy |
| SpO2, ABG | ↓ O2, ↑ CO2 (late) | Monitor respiratory failure |
| Pulmonary function (FVC, NIF) | Declining | Serial bedside testing - key early warning |
| Serum CK | Elevated (sea snake, krait) | Rhabdomyolysis |
| Urine | Myoglobinuria (sea snake) | Renal involvement |
| ECG | Bradycardia, arrhythmias (late) | Autonomic effects |
Baseline and serial measurement of inspiratory pressure and vital capacity is particularly important in elapid bites to detect early respiratory muscle weakness before clinical deterioration. - Tintinalli's Emergency Medicine
AIRWAY ← PRIORITY #1
- Assess swallowing (ask patient to swallow; watch for pooling saliva)
- Position: semi-recumbent, lateral if decreased consciousness (aspiration risk)
- Have intubation equipment ready at bedside from the start
BREATHING
- SpO2 monitoring continuously
- Serial FVC/NIF measurements every 30-60 min
- Low threshold for intubation (see below)
CIRCULATION
- IV access × 2
- IV fluids (normal saline) - usually not needed early but have ready
| Consideration | Detail |
|---|---|
| Antivenom type | Polyvalent antivenom (covers cobra, krait, Russell's viper, Echis) in India |
| Dose | 8-10 vials IV (same dose for adults and children) |
| Route | IV infusion in 250-500 mL normal saline over 1 hour |
| Skin test | NOT recommended (unreliable, causes delay) |
| When to repeat | If neurological signs progress at 1-2 hours, repeat same dose |
| Maximum | Up to 10 vials total in severe cases |
Harrison's 22E recommends an "acetylcholinesterase inhibitor trial" for any cranial nerve abnormality in snakebite - even as an initial diagnostic-therapeutic step.
| Situation | Management |
|---|---|
| Bulbar paralysis (unable to swallow/cough) | Early intubation, nasogastric tube, strict aspiration precautions |
| Sea snake bite | Antivenom + IV fluids for myoglobinuria; monitor renal function; dialysis if AKI |
| Krait bite while sleeping (no witnessed bite) | High suspicion - bilateral ptosis on waking is virtually pathognomonic; treat as neurotoxic even without confirmed history |
| Spitting cobra - eye exposure | Immediate copious irrigation with water/saline; NO antivenom needed (no systemic absorption); ophthalmology review for corneal injury |
| Exotic/non-native elapid | Contact local zoo / Association of Zoos and Aquariums antivenom index; mortality untreated = 20-30% (cobra) to ~100% (mamba) |
| Feature | Colubrine (Neurotoxic) Cobra, Krait | Viperine (Haemotoxic) Russell's, Echis |
|---|---|---|
| Local swelling | Minimal/absent | Marked, rapidly spreading |
| Pain at bite | Slight | Severe, immediate |
| Onset of symptoms | 30 min - 12 hours | Immediate to 15 min |
| Paralysis | Yes - descending | No |
| Speech/swallowing | Difficult | Normal |
| Salivation | Increased | Normal |
| Pupils | Normal | Dilated, non-reactive |
| Blood pressure | Normal (early) | Hypotension |
| Bleeding/clotting | Normal | Abnormal (coagulopathy) |
| 20WBCT | Clots | Non-clotting |
| Dark urine | Sea snakes | Haemoglobinuria/myoglobin |
| Death | Respiratory paralysis | Haemorrhage / AKI |
What does serum sickness mean in snake bite
SEQUENCE OF EVENTS:
1. Antivenom given IV
(Contains foreign animal proteins = antigens)
↓
2. Patient's immune system recognizes these
as foreign (7-14 days later)
↓
3. Patient produces IgG/IgM antibodies
against antivenom proteins
↓
4. Antigen (antivenom) + Antibody (patient's)
= IMMUNE COMPLEXES form in circulation
↓
5. Immune complexes deposit on:
- Blood vessel walls
- Glomerular basement membrane (kidney)
- Joint synovium
- Skin
↓
6. Complement activation + Leukocyte
infiltration → INFLAMMATION & tissue damage
↓
SERUM SICKNESS SYMPTOMS
| Reaction Type | Timing | Mechanism |
|---|---|---|
| Anaphylaxis (early reaction) | During infusion / within minutes-hours | Type I (IgE-mediated, immediate) |
| Serum sickness (late reaction) | 7-14 days after antivenom | Type III (immune complex, delayed) |
| Symptom | Description |
|---|---|
| Fever | Low-grade to moderate |
| Skin rash | Urticaria (hives), erythematous eruptions, itching - usually the first sign |
| Arthralgia / Arthritis | Joint pain and swelling - multiple joints |
| Myalgia | Muscle aches and pains |
| Lymphadenopathy | Swollen lymph glands |
| Peripheral oedema | Swelling of hands, feet |
| Glomerulonephritis | Renal involvement (less common, manifests as proteinuria, haematuria) |
| Neurologic symptoms | Rare - peripheral neuropathy |
| Antivenom Type | Serum Sickness Rate |
|---|---|
| Old equine (horse-derived) whole IgG antivenom | Very high - up to 50%+ |
| Ovine (sheep-derived) Fab fragment antivenom (CroFab) | 13-16% |
| Modern Fab₂ fragment antivenoms | Lower than whole IgG |
| Step | Drug | Dose | Duration |
|---|---|---|---|
| First line | Oral prednisolone (corticosteroid) | 1-2 mg/kg/day | Until symptoms resolve, then taper over 1-2 weeks |
| Adjunct | Oral antihistamine (cetirizine / diphenhydramine) | Standard doses | For itch and urticaria |
| Adjunct | Analgesics (paracetamol) | Standard doses | For fever and joint pain |
| Severe cases | IV methylprednisolone | 125 mg IV bolus | Short course |
| Refractory | Plasmapheresis | - | Removes immune complexes from circulation |
Do NOT use NSAIDs (aspirin, ibuprofen) - these are already contraindicated post-snakebite due to bleeding risk from residual coagulopathy.
Scorpion bite
"scorpion envenomation" AND "management" AND "antivenom"
"scorpion sting" treatment prazosin antivenom

| Species | Region | Main Effect |
|---|---|---|
| Hottentotta tamulus (Indian Red Scorpion) | India, Nepal, Pakistan | Autonomic storm, pulmonary oedema, myocarditis - most dangerous in India |
| Leiurus quinquestriatus | Middle East, North Africa | Massive catecholamine release, cardiac failure; 50% mortality in untreated children |
| Androctonus spp. | North Africa, Middle East | Cardiovascular toxicity, pulmonary oedema |
| Mesobuthus tamulus | India | Catecholamine excess, cardiovascular |
| Centruroides sculpturatus | USA (Arizona) | Neuromuscular toxicity, cranial nerve dysfunction |
| Tityus serrulatus | Brazil | Catecholamine release; also acute pancreatitis |
| Tityus trinitatis | Trinidad | Acute pancreatitis |
| Hemiscorpius lepturus | Iran | Cytotoxic (NOT neurotoxic) - local necrosis, haemolysis, AKI |
| Parabuthus, Buthotus | South Africa | CNS toxicity |
Behaviour: Nocturnal; hide in shoes, clothing, bedding, rock crevices, under bark. Sting only in self-defence. - Harrison's 22E
Scorpion toxin (peptide neurotoxin)
↓
Binds voltage-gated Na⁺ channels
(Sites 3 & 4 on the channel)
↓
Prevents channel inactivation
→ Channels stay OPEN
↓
Sustained, excessive nerve depolarization
↓
┌─────────────────────────────────────────┐
│ SOMATIC nervous system: │
│ Motor nerve hyperexcitability │
│ → muscle twitching, jerking │
│ │
│ AUTONOMIC nervous system: │
│ Sympathetic + parasympathetic │
│ simultaneous stimulation │
│ → AUTONOMIC STORM │
└─────────────────────────────────────────┘
Systemic toxicity occurs in <10% of stings overall. - Tintinalli's EM
| Grade | Features |
|---|---|
| Grade 1 | Local pain and/or paraesthesia at sting site only |
| Grade 2 | Pain and/or paraesthesia remote from sting site |
| Grade 3 | Cranial nerve dysfunction OR somatic skeletal neuromuscular dysfunction |
| Grade 4 | Both cranial nerve AND somatic skeletal neuromuscular dysfunction |
| Test | Relevance |
|---|---|
| ECG | Arrhythmias, ST changes (myocarditis) |
| Chest X-ray | Pulmonary oedema |
| Troponin, CK-MB | Myocardial injury |
| Echocardiography | Depressed myocardial contractility - key bedside test |
| Serum amylase/lipase | Pancreatitis (Tityus spp.) |
| CBC, renal function | Haemolysis, AKI (Hemiscorpius) |
| Serum CK, urine myoglobin | Rhabdomyolysis |
| Blood glucose | Hyperglycaemia from catecholamine surge |
GRADE 1-2 (Local effects only)
│
├─ Local wound care
├─ Analgesia (paracetamol / NSAIDs / local lidocaine infiltration)
├─ Tetanus prophylaxis
└─ Observe 4-6 hours; discharge with return precautions
GRADE 3-4 (Systemic effects)
│
├─ Hospital admission
├─ Monitor: ECG, SpO2, BP, urine output
├─ IV access
├─ Consider antivenom
└─ Treat specific complications (see below)
Dose: Oral prazosin 30 μg/kg/dose at 3-hour intervals until clinical syndrome resolves - Goldman-Cecil Medicine International Edition
| Problem | Drug |
|---|---|
| Hypertension | Nifedipine, nitroprusside, hydralazine, or prazosin |
| Pulmonary oedema | Prazosin or nitroglycerin (reduce preload/afterload); ventilatory support |
| Cardiogenic shock | Dobutamine (inotrope); avoid vasopressors that worsen catecholamine surge |
| Bradyarrhythmia | Atropine |
| Tachyarrhythmia | Antiarrhythmics; treat underlying cause |
Do NOT use atropine routinely - use only for clinically significant bradycardia. Atropine can worsen tachycardia and hypertension in catecholamine excess states.
| Situation | Management |
|---|---|
| Children | Higher risk of severe/fatal envenomation; lower antivenom threshold; close monitoring mandatory |
| Pulmonary oedema | Prazosin + nitroglycerin + dobutamine (if cardiogenic); CPAP/intubation if needed |
| Acute pancreatitis (Tityus spp.) | IV fluids, bowel rest, analgesia, monitor amylase/lipase |
| Haemolysis + AKI (Hemiscorpius) | IV fluids; dialysis if oliguric renal failure; antivenom (available in Iran) |
| Pregnancy | Cautious antivenom use - weigh fetal risk vs. maternal benefit |
| Feature | Hottentotta tamulus (India) | Centruroides (USA) |
|---|---|---|
| Primary toxicity | Cardiovascular (catecholamine storm) | Neuromuscular |
| Key symptoms | Hypertension, pulmonary oedema, myocarditis | Cranial nerve palsy, muscle jerking, hypersalivation |
| Local swelling | Minimal | Minimal |
| Specific drug | Prazosin | Midazolam (sedation) |
| Antivenom | Available and effective | Anascorp (FDA-approved) |
| Mortality | High in children if untreated | Fatal mainly in very young/elderly |
| ❌ Avoid | Reason |
|---|---|
| Ice directly on wound | Ice packs are fine, but prolonged direct ice causes additional tissue injury |
| Atropine routinely | Worsens tachycardia; only for symptomatic bradycardia |
| Opiates without monitoring | Respiratory depression + neurotoxin = dangerous; close monitoring mandatory |
| Tourniquet | Not effective for scorpion envenomation |
| Incision/suction | Ineffective, harmful |
| Grade | Disposition |
|---|---|
| Grade 1 | Observe 4-6 hours, discharge if no systemic progression |
| Grade 2 | Observe minimum 6-8 hours; discharge if stable |
| Grade 3-4 | Admit to hospital / ICU; antivenom; specific management |
| Children with any systemic sign | Admit regardless of grade |
Suggest metformin Dapaglifozin tablet dosage in this condition
Scorpion bite management
| Species | Region | Primary Effect |
|---|---|---|
| Hottentotta tamulus | India, Nepal, Pakistan | Autonomic storm, pulmonary oedema, myocarditis |
| Leiurus quinquestriatus | Middle East, N. Africa | Cardiac failure; 50% mortality in children |
| Androctonus spp. | N. Africa, Middle East | Cardiovascular toxicity |
| Mesobuthus tamulus | India | Catecholamine excess |
| Centruroides sculpturatus | USA (Arizona) | Neuromuscular, cranial nerve dysfunction |
| Tityus serrulatus | Brazil | Catecholamines + acute pancreatitis |
| Hemiscorpius lepturus | Iran | Cytotoxic - necrosis, haemolysis, AKI |
| Grade | Features |
|---|---|
| 1 | Local pain/paraesthesia at sting site only |
| 2 | Pain/paraesthesia remote from sting site |
| 3 | Cranial nerve dysfunction OR skeletal neuromuscular dysfunction |
| 4 | BOTH cranial nerve AND skeletal neuromuscular dysfunction |
| Test | Relevance |
|---|---|
| ECG | Arrhythmias, ST changes (myocarditis) |
| Chest X-ray | Pulmonary oedema |
| Echo (bedside) | Depressed contractility |
| Troponin, CK-MB | Myocardial injury |
| Amylase/lipase | Pancreatitis (Tityus) |
| Serum CK, urine myoglobin | Rhabdomyolysis |
| Renal function, CBC | Haemolysis, AKI |
| Blood glucose | Hyperglycaemia from catecholamine surge |
GRADE 1-2
├─ Paracetamol / NSAID / local lidocaine for pain
├─ Tetanus prophylaxis
└─ Observe 4-6 hours; discharge with return precautions
GRADE 3-4
├─ Hospital admission / ICU
├─ IV access, ECG, SpO2, BP monitoring
├─ Antivenom (if available)
└─ Treat specific complications
| Drug | Indication | Dose |
|---|---|---|
| Antivenom (IV preferred) | Grade 3-4; any systemic sign | 3 vials IV; repeat 1 vial q30-60 min as needed |
| Prazosin (α1-blocker) | Indian Red Scorpion - hypertension, autonomic storm | 30 μg/kg/dose orally every 3 hours until syndrome resolves |
| Midazolam (IV infusion) | Neuromuscular agitation, muscle jerking | Titrate to effect; monitor respiration closely |
| Nifedipine / Nitroprusside / Hydralazine | Hypertension | Standard antihypertensive doses |
| Nitroglycerin | Pulmonary oedema (reduce preload) | Standard doses |
| Dobutamine | Cardiogenic shock / pulmonary oedema with low output | Inotropic support |
| Atropine | Symptomatic bradyarrhythmia ONLY | 0.6 mg IV; repeat as needed |
Prazosin is the cornerstone drug for Indian Red Scorpion - it directly blocks the alpha-1 receptors that mediate the catecholamine-driven hypertension and pulmonary oedema.
| ❌ Avoid | Reason |
|---|---|
| Atropine routinely | Worsens tachycardia and hypertension |
| Opiates without monitoring | Respiratory depression risk with neurotoxin |
| Tourniquet | Ineffective |
| Incision / suction | Harmful, ineffective |
| Disposition | |
|---|---|
| Grade 1-2, adult, asymptomatic after 4-6 hrs | Discharge with precautions |
| Grade 3-4 ANY patient | Admit to hospital |
| Any child with systemic sign | Admit - higher mortality risk |
| Pulmonary oedema / shock | ICU |
Sulphas poisoning
"aluminium phosphide" poisoning management treatment
"aluminium phosphide" poisoning mortality treatment
PMID: 40874872
PMID: 42145294
ALP + Moisture (gastric HCl/water)
↓
Al(OH)₃ + PH₃ (Phosphine gas)
↓
Inhibits Cytochrome Oxidase (Complex IV)
of mitochondrial electron transport chain
↓
┌──────────────────────────────────────┐
│ Cell cannot produce ATP │
│ ALL organs affected simultaneously │
│ → Cardiogenic shock (main killer) │
│ → Multi-organ failure │
└──────────────────────────────────────┘
| Parameter | Detail |
|---|---|
| Tablet weight | 3 g per tablet (56% active ALP) |
| Phosphine per tablet | 1 g of PH₃ released per tablet |
| Fatal dose | 1-3 tablets (1-3 g) - even a fragment can kill |
| Fatal period | 6-12 hours (majority of deaths within 24 hrs) |
| Inhalation | PH₃ at 400-600 ppm fatal within 1 hour |
| Mortality | 35-100% - among the highest of all pesticide poisonings |
| Odour | Characteristic garlicky / fishy smell |
| Colour | Grayish-green tablets |
| Severity | Features |
|---|---|
| Mild | Nausea, vomiting, headache, abdominal pain, mucous membrane irritation → usually recover |
| Moderate | Ataxia, paraesthesia, tremors, diplopia, jaundice, muscular weakness, incoordination |
| Severe / Fatal | ARDS, cardiac arrhythmias, congestive heart failure, pulmonary oedema, convulsions, coma |
| System | Manifestations |
|---|---|
| GIT | Nausea, vomiting, retrosternal / epigastric burning pain, diarrhoea, intense thirst, massive GI bleeding |
| CVS | Hypotension, shock, arrhythmias (sinus tachycardia, bradycardia, heart block), myocarditis, pericarditis, acute congestive heart failure → Cardiogenic shock = most common cause of death |
| Respiratory | Cough, dyspnoea, tightness in chest, cyanosis, pulmonary oedema, respiratory failure, ARDS |
| CNS | Headache, dizziness, restlessness, excitement/agitation, convulsions, altered consciousness, hypoxic encephalopathy, coma |
| Renal | Oliguria, renal failure |
| Hepatic | Jaundice, hepatitis, hepatomegaly |
| Other | Cold clammy skin, hypocalcaemia, tetany, ECG abnormalities, muscle wasting, bleeding diathesis (capillary damage) |
Key clinical hallmark: Garlicky/fishy odour on breath + cardiovascular collapse in a young patient from rural India = ALP poisoning until proven otherwise.
AgNO₃ (white) + PH₃ → Ag (black) + H₃PO₄
The patient's vomit and breath contain phosphine gas. Healthcare workers and relatives must:
| Method | Details |
|---|---|
| Gastric lavage | With potassium permanganate (KMnO₄) - oxidizes phosphine to non-toxic phosphate; repeat 2-3 times. Only after endotracheal intubation to protect airway. |
| Alternative lavage solutions | 3-5% sodium bicarbonate, 1% copper sulphate, mineral oil / liquid paraffin |
| Activated charcoal | 100 g in sorbitol (NOT water - water accelerates phosphine release); 240 mL for every 30 g; adsorbs phosphine |
| Antacids | Reduce gastric acid → slow phosphine generation; reduce absorption |
| Liquid paraffin | Aids excretion of ALP and phosphine from gut |
Controversy: Some recent guidelines caution against gastric lavage because adding water/moisture to remaining ALP in stomach accelerates phosphine generation. Intubate first, then decide.
| Problem | Treatment |
|---|---|
| Shock / Hypotension | IV fluids 4-6 litres in first 3-6 hrs (50% normal saline) + hydrocortisone |
| Cardiogenic shock | Low dose dopamine 4-6 μg/kg/min IV infusion |
| Arrhythmias | Magnesium sulphate (see below) + anti-arrhythmics as needed |
| Refractory cardiogenic shock | VA-ECMO (see below) |
Monitor for hypermagnesaemia especially in renal failure (MgSO₄ is contraindicated or dose-reduced when eGFR severely impaired)
| Measure | Detail |
|---|---|
| Calcium IV | For hypocalcaemia and tetany |
| Antibiotics | For secondary infections |
| Renal support | Haemodialysis / peritoneal dialysis for renal failure AND metabolic acidosis |
| Seizure control | Benzodiazepines |
| Monitoring | Continuous ECG, SpO2, ABG, urine output, electrolytes |
| Finding | Result |
|---|---|
| Survival with VA-ECMO | 67.9% |
| Mortality without admission | 100% |
| Median ECMO duration | 48 hours |
| ECG abnormalities on presentation | 94.9% |
| Multi-organ dysfunction | 76.9% |
| Concurrent dialysis needed | 67.9% |
| Treatment | Drug/Dose | Purpose |
|---|---|---|
| Gastric lavage | KMnO₄ solution (after intubation) | Oxidize phosphine |
| Activated charcoal | 100 g in sorbitol | Adsorb phosphine |
| Antacids + Liquid paraffin | Standard doses | Reduce absorption, aid excretion |
| Magnesium sulphate | 1 g IV bolus → 1-1.5 g q6h × 5-7 days | Arrhythmia, organ protection |
| NaHCO₃ | 20 mL/kg 8.4% aggressive + 50 mEq q15 min | Correct metabolic acidosis |
| Hydrocortisone | 400 mg IV q4-6 hours | Pulmonary oedema, shock |
| Dopamine | 4-6 μg/kg/min infusion | Cardiogenic shock |
| IV fluids | 4-6 L in 3-6 hrs (50% NS) | Volume resuscitation |
| Calcium IV | As needed | Hypocalcaemia, tetany |
| RRT / Haemodialysis | As needed | Acidosis, renal failure |
| VA-ECMO | Last resort | Refractory cardiogenic shock |
| O₂ / Mechanical ventilation | As needed | Respiratory failure |

| Organ | Findings |
|---|---|
| Stomach | Congestion, oedema, leucocytic infiltration, sloughing of mucosa |
| Lungs | Congestion, oedema, desquamation of respiratory epithelium, thickened alveoli |
| Kidneys | Congestion, necrosis, tubular degeneration |
| Adrenals | Congestion, haemorrhage, necrosis, lipid depletion in cortex |
| Heart | Congestion, oedema, fragmentation of fibres, focal necrosis, leucocytic infiltration |
| Brain | Congestion, oedema |
Decide a treatment line with dosages for the following report
| Parameter | Value | Status |
|---|---|---|
| HbA1c | 8.32% | ⬆ HIGH - Poor control (target <7.0%) |
| Average Blood Glucose | 192.08 mg/dL | ⬆ Poor control |
| Serum Triglycerides | 171.96 mg/dL | ⬆ Borderline high |
| Total Cholesterol | 168.64 mg/dL | ✅ Normal |
| LDL | 85.93 mg/dL | ✅ Normal |
| HDL | 48.32 mg/dL | ✅ Normal |
| Investigation | Why Needed | Threshold |
|---|---|---|
| Serum Creatinine / eGFR | Dapagliflozin unsafe if eGFR <45; Metformin unsafe if eGFR <30 | eGFR must be ≥45 |
| LFT (Liver Function) | Dapagliflozin dose reduced in hepatic failure | |
| Urine R/E | Rule out UTI before starting (SGLT2i increases UTI risk) | |
| Vitamin B12 | Metformin causes B12 deficiency over time |
| Phase | Dose | Timing |
|---|---|---|
| Week 1 (if not already at this dose) | Metformin 500 mg | Once daily with breakfast |
| Week 2 | Metformin 500 mg | Twice daily (morning + evening with meals) |
| Week 4 | Metformin 1000 mg | Twice daily with meals |
| Target maintenance dose | Metformin 1000 mg BD (2000 mg/day) | Morning + evening with food |
Maximum effective dose: 2000 mg/day (little additional benefit above this). Absolute maximum is 2550 mg/day. - Katzung's Basic & Clinical Pharmacology 16th Ed.
| Details | |
|---|---|
| Drug | Dapagliflozin (Farxiga / Forxiga) |
| Starting dose | 5 mg once daily (morning, with or without food) |
| Maintenance dose | 10 mg once daily (after 2-4 weeks if tolerated) |
| Standard dose | 10 mg once daily - this is the usual full dose |
| Timing | Morning, with or without food |
| Condition | Requires eGFR ≥45 before starting; not for glycaemic effect if eGFR <45 |
Standard dose of dapagliflozin for type 2 diabetes is 10 mg once daily. The 5 mg dose is the starting/cautious dose and the recommended dose in hepatic impairment. - Katzung's Basic & Clinical Pharmacology 16th Ed.
| Combination Tablet | Dose | Frequency |
|---|---|---|
| Dapagliflozin 10 mg + Metformin 500 mg | 1 tablet | Twice daily with meals |
| OR Dapagliflozin 10 mg + Metformin 1000 mg | 1 tablet | Twice daily with meals |
| Intervention | Target |
|---|---|
| Diet | Low refined carbohydrate, low saturated fat; small frequent meals |
| Exercise | 30 min brisk walking 5 days/week (reduces HbA1c by ~0.5-0.7% independently) |
| Triglycerides | Avoid alcohol, refined sugars, fruit juices; reduce rice and wheat portions |
| Weight loss | Target 5-10% body weight reduction if overweight |
| Parameter | Frequency |
|---|---|
| HbA1c | Every 3 months after medication change; target <7.0% |
| Fasting + PP blood glucose | Monthly initially |
| eGFR / Creatinine | Before starting; then every 6 months |
| Serum Triglycerides | Recheck at 3 months (should improve with glycaemic control) |
| Vitamin B12 | Annually (long-term metformin use) |
| Urine R/E | If symptoms of UTI/genital infection develop |
| Drug | Warn About |
|---|---|
| Metformin | Nausea, diarrhoea (take with food; usually settles in 2 weeks); rare lactic acidosis; B12 deficiency long-term |
| Dapagliflozin | Genital fungal infection (keep area clean/dry); UTI symptoms (burning micturition); increased urination; stop before any surgery or prolonged fasting (DKA risk); stay well hydrated |
1. Metformin 500 mg → titrate to 1000 mg BD with meals
(or Metformin XR 1000 mg OD if GI intolerance)
2. Dapagliflozin 10 mg → once daily morning
(Start at 5 mg for 2-4 weeks, then increase to 10 mg)
OR: Fixed combination tablet:
Dapagliflozin 10 mg + Metformin 1000 mg — 1 tablet BD with meals
3. Lifestyle: Diet + 30 min walking × 5 days/week
Pre-check: eGFR, creatinine, LFT, urine R/E before starting Dapagliflozin
Follow-up: HbA1c at 3 months — target <7.0%
⚠️ Disclaimer: This is a clinical guidance suggestion based on the lab values provided. All prescriptions must be finalised by the treating physician after complete clinical evaluation including history, examination, renal/liver function tests, and assessment of contraindications.